Lecture Details - Overview

This activity is part of PER's Integrated Oncology Learning Series: A Focus on Multiple Myeloma

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

E-Lert: Multiple Myeloma

Release Date: December 29, 2009| Expiration Date: December 29, 2010
0.5 AMA PRA Category 1 Credit(s)™| Dec 29, 2009, E-lert

Lecture Overview

Remarkable progress has been made in the treatment of multiple myeloma (MM) as a result of the introduction of autologous stem cell transplantation and the incorporation of targeted agents into the therapeutic paradigm. Targeted agents are now being evaluated in patients with smoldering MM to determine whether they can provide benefit for those at high risk of disease progression. Treatment of MM has evolved from standard chemotherapy alone to more novel and efficacious doublet and triplet combinations that include immunomodulatory agents or a proteasome inhibitor. While these measures have prolonged survival, relapse remains inevitable. Newer approaches to improving outcomes include evaluation of multitargeted-agent regimens and design of novel synergistic combinations. Efforts to prolong first remission in newly diagnosed MM include appraisal of the maintenance and consolidation strategies following transplantation or first-line therapy for those who decline or are ineligible for stem cell support. The increased response rate and depth of response seen with these contemporary regimens and strategies in the frontline treatment of MM has resulted in reinvestigation of the role and timing of transplantation.

The purpose of this activity is to apprise physicians of emerging strategies in phase III evaluation in the frontline treatment of patients with MM.

This educational activity is intended for medical oncologists and hematologists involved in the care of patients with MM. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Upon completion of this educational activity, you should be able to:

  • Discuss the data derived from trials evaluating new combinations of proteasome inhibitors and immunomodulatory agents in the frontline treatment of patients with transplantation-eligible MM
  • Assess emerging maintenance and consolidation strategies in the frontline treatment of elderly patients with MM
  • Evaluate the efficacy and toxicity of investigational 3- and 4-drug combinations of targeted agent plus chemotherapy for elderly patients with MM or patients with transplantation-ineligible MM

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by December 29, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Untitled Document

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Suzanne Lentzsch, MD, PhD
Research Funding – Celgene Corporation
Speaker’s Bureau – Celgene Corporation

PER Editorial Staff
No relevant relationships to disclose

This CME activity includes discussion of investigational and/or unlabeled uses of drugs, including the use of lenalidomide/dexamethasone in high-risk smoldering multiple myeloma; lenalidomide/dexamethasone, lenalidomide/melphalan/prednisone, bortezomib/dexamethasone, and thalidomide/bortezomib plus dexamethasone, prednisone, or melphalan/prednisone in newly diagnosed multiple myeloma; and lenalidomide, bortezomib/thalidomide, and bortezomib/prednisone as consolidation and/or maintenance therapy in newly diagnosed multiple myeloma. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by Celgene Corporation.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer
The views and opinions expressed in this learning activity are those of the presenter and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenter and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, E-Lert: Multiple Myeloma
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

8690

Educational Grants

An educational grant for this activity was provided by:


  1. Celgene Corporation